Tryptophan and the immune response

Immunology and Cell Biology

Volumn 81, Issue 4, 2003, Pages 247-265

  Moffett, John R ^a   Namboodiri, Ma Aryan ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Dendritic cell; Indoleamine 2, 3 dioxygenase; Kynurenine; Macrophage; NAD; Niacin; Poly ADP ribose polymerase; Quinolinic acid; Tolerance; Tryptophan dioxygenase

Indexed keywords

ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINIC ACID; QUINOLINIC ACID; TRYPTOPHAN;

AMINO ACID METABOLISM; CELL TYPE; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; FETUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; THEORY;

ANIMALS; DENDRITIC CELLS; DIOXYGENASES; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; NAD; OXYGENASES; POLY(ADP-RIBOSE) POLYMERASES; QUINOLINIC ACID; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 0042848767     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2003.t01-1-01177.x     Document Type: Review

References (133)

1. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 2001; 64: 185-218.
2. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002; 1: 609-20.
3. Satyanarayana U, Narasinga Rao BS. Effect of diet restriction on some key enzymes tryptophan-NAD pathway in rats. J. Nutr. 1977; 107: 2213-18.
4. Satyanarayana U, Rao BS. Effect of dietary protein level on some key enzymes of the tryptophan-NAD pathway. Br. J. Nutr. 1977; 38: 39-45.
5. Satyanarayana U, Rao BS. Dietary tryptophan level and the enzymes of tryptophan NAD pathway. Br. J. Nutr. 1980; 43: 107-13.
6. McCreanor GM, Bender DA. The metabolism of high intakes of tryptophan, nicotinamide and nicotinic acid in the rat. Br. J. Nutr. 1986; 56: 577-86.
7. Shibata K. Nutritional factors that regulate on the conversion of 1-tryptophan to niacin. Adv. Exp. Med. Biol. 1999; 467: 711-16.
8. Badawy AA, Evans M. Animal liver tryptophan pyrrolases: Absence of apoenzyme and of hormonal induction mechanism from species sensitive to tryptophan toxicity. Biochem. J. 1976; 158: 79-88.
9. Yang JN, Carlson JR. Effects of high tryptophan doses and two experimental rations on the excretion of urinary tryptophan metabolites in cattle. J. Nutr. 1972; 102: 1655-65.
10. Gross B, Ronen N, Honigman S, Livne E. Tryptophan toxicity - time and dose-response in rats. Adv. Exp. Med. Biol. 1999; 467: 507-16.
11. Ronen N, Livne E, Gross B. Oxidative damage in rat tissue following excessive 1-tryptophan and atherogenic diets. Adv. Exp. Med. Biol. 1999; 467: 497-505.
12. Gross B, Ronen N, Reznick A, Mokady S, Honigman S, Livne E. Biochemical and morphological changes observed in rat muscles following consumption of excessive 1-tryptophan and atherogenic diets. Adv. Exp. Med. Biol. 1996; 398: 575-8.
13. Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N. Engl. J. Med. 1990; 322: 874-81.
14. Stahl JL, Cook EB, Pariza MA, Cook ME, Graziano FM. Effect of 1-tryptophan supplementation on eosinophils and eotaxin in guinea pigs. Exp. Biol. Med. (Maywood.) 2001; 226: 177-84.
15. Shibata K, Motooka K, Murata K. The differences in growth and activity of the tryptophan-NAD pathway between Wistar and Sprague Dawley strains of rats fed on tryptophan-limited diet. J. Nutr. Sci. Vitaminol. (Tokyo) 1982; 28: 11-19.
16. Fu CS, Swendseid ME, Jacob RA, McKee RW. Biochemical markers for assessment of niacin status in young men: levels of erythrocyte niacin coenzymes and plasma tryptophan. J. Nutr. 1989; 119: 1949-55.
17. Moffett JR, Blinder KL, Venkateshan CN, Namboodiri MA. Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell Tissue Res. 1998; 293: 525-34.
18. Espey MG, Namboodiri MA. Selective metabolism of kynurenine in the spleen in the absence of indoleamine 2,3-dioxygenase induction. Immunol. Lett. 2000; 71: 67-72.
19. Bender DA, Magboul BI, Wynick D. Probable mechanisms of regulation of the utilization of dietary tryptophan, nicotinamide and nicotinic acid as precursors of nicotinamide nucleotides in the rat. Br. J. Nutr. 1982; 48: 119-27.
20. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 1983; 158: 670-89.
21. Tennenberg SD, Fey DE, Lieser MJ. Oxidative priming of neutrophils by interferon-gamma. J. Leukoc. Biol. 1993; 53: 301-8.
22. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Induction of indoleamine 2,3-dioxygenase in human cells in vitro. Adv. Exp. Med. Biol. 1991; 294: 505-9.
23. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Wachter H. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem. J. 1989; 262: 861-6.
24. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc. Natl Acad. Sci. USA 1981; 78: 129-32.
25. Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Arch. Biochem. Biophys. 1980; 203: 343-51.
26. Yoshida R, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc. Natl Acad. Sci. USA 1978; 75: 3998-4000.
27. Burke F, Knowles RG, East N, Balkwill FR. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int. J. Cancer 1995; 60: 115-22.
28. Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox. Report 2000; 5: 101-4.
29. Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv. Exp. Med. Biol. 1996; 398: 285-9.
30. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 1991; 294: 425-35.
31. Pfefferkom ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl Acad. Sci. USA 1984; 81: 908-12.
32. Yoshida R, Park SW, Yasui H, Takikawa O. Tryptophan degradation in transplanted tumor cells undergoing rejection. J. Immunol. 1988; 141: 2819-23.
33. Wood JM, Ehrke C, Schallreuter KU. Tryptophan protects human melanoma cells against gamma-interferon and tumour necrosis factor-alpha: a unifying mechanism of action. Melanoma. Res. 1991; 1: 177-85.
34. Aune TM, Pogue SL. Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide. J. Clin. Invest. 1989; 84: 863-75.
35. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999; 189: 1363-72.
36. Salter M, Pogson CI. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem. J. 1985; 229: 499-504.
37. Brady FO. Tryptophan 2,3-dioxygenase: a review of the roles of the heme and copper cofactors in catalysis. Bioinorg. Chem. 1975; 5: 167-82.
38. Sainio EL. The role of adrenal hormones in the activation of tryptophan 2,3-dioxygenase by nicotinic acid in rat liver. Methods Find. Exp. Clin. Pharmacol. 1997; 19: 465-70.
39. Sainio EL, Sainio P. Comparison of effects of nicotinic acid or tryptophan on tryptophan 2,3-dioxygenase in acute and chronic studies. Toxicol. Appl. Pharmacol. 1990; 102: 251-8.
40. Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O. Interferon: a mediator of indoleamine 2,3-dioxygenase induction by lipopolysaccharide, poly (I), X poly (C), and pokeweed mitogen in mouse lung. Arch. Biochem. Biophys. 1986; 249: 596-604.
41. Saito K, Markey SP, Heyes MP. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neurosci. 1992; 51: 25-39.
42. Saito K, Crowley JS, Markey SP, Heyes MP. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J. Biol. Chem. 1993; 268: 15 496-503.
43. Schwarcz R, Foster AC, French ED, Whetsell WO Jr, Köhler C. Excitotoxic models for neurodegenerative disorders. Life Sci. 1984; 35: 19-32.
44. Whetsell WO Jr, Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci. Lett. 1989; 97: 271-5.
45. Stone TW. Endogenous neurotoxins from tryptophan. Toxicon. 2001; 39: 61-73.
46. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 2000; 107: 343-53.
47. Heyes MP, Brew BJ, Martin A et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol. 1991; 29: 202-9.
48. Heyes MP, Rubinow D, Lane C, Markey SP. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann. Neurol. 1989; 26: 275-7.
49. Bender DA. The kynurenine pathway of tryptophan metabolism. In: Stone TW, ed. Quinolinic Acid and the Kynurenines. Boca Raton, FL, USA: CRC Press, 1989; 4-38.
50. Köhler C, Eriksson LG, Flood PR, Hardie JA, Okuno E, Schwarcz R. Quinolinic acid metabolism in the rat brain: Immunohistochemical identification of 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase in the hippocampal region. J. Neurosci. 1988; 8: 975-87.
51. Roberts RC, McCarthy KE, Du F, Ottersen OP, Okuno E, Schwarcz R. 3-Hydroxyanthranilic acid oxygenase-containing astrocytic processes surround glutamate-containing axon terminals in the rat striatum. J. Neurosci. 1995; 15: 1150-61.
52. Roberts RC, McCarthy KE, Du F, Okuno E, Schwarcz R. Immunocytochemical localization of the quinolinic acid synthesizing enzyme, 3-hydroxyanthranilic acid oxygenase, in the rat substantia nigra. Brain Res. 1994; 650: 229-38.
53. Moffett JR, Espey MG, Namboodiri MA. Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue. Res. 1994; 278: 461-9.
54. Saito K, Chen CY, Masana M, Crowley JS, Markey SP, Heyes MP. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells). Biochem. J. 1993; 291: 11-14.
55. Venkateshan CN, Narayanan R, Espey MG et al. Immunocytochemical localization of the endogenous neuroexcitotoxin quinolinate in human peripheral blood monocytes/macrophages and the effect of human T-cell lymphotropic virus type I infection. Proc. Natl Acad. Sci. USA 1996; 93: 1636-41.
56. Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 2001; 120: 190-8.
57. Heyes MP, Saito K, Jacobowitz D, Markey SP, Takikawa O, Vickers JH. Poliovirus induces indoleamine-2,3-dioxygenase and quinolinic acid synthesis in macaque brain. FASEB J. 1992; 6: 2977-89.
58. Moffett JR, Espey MG, Gaudet SJ, Namboodiri MA. Antibodies to quinolinic acid reveal localization in select immune cells rather than neurons or astroglia. Brain Res. 1993; 623: 337-40.
59. Moffett JR, Espey MG, Saito K, Namboodiri MA. Quinolinic acid immunoreactivity in cells within the choroid plexus, leptomeninges and brain vasculature of the immune stimulated gerbil. J. Neuroimmunol. 1994; 54: 69-73.
60. Espey MG, Tang Y, Morse HC 3rd, Moffett JR, Namboodiri MA. Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis. AIDS 1996; 10: 151-8.
61. Moffett JR, Els T, Espey MG, Walter SA, Streit WJ, Namboodiri MA. Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes. Exp. Neurol. 1997; 144: 287-301.
62. Espey MG, Moffett JR, Namboodiri MA. Temporal and spatial changes of quinolinic acid immunoreactivity in the immune system of lipopolysaccharide-stimulated mice. J. Leukoc. Biol. 1995; 57: 199-206.
63. Lehrmann E, Molinari A, Speciale C, Schwarcz R. Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum. Exp. Brain Res. 2001; 141: 389-97.
64. Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from 1-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993; 116: 1425-50.
65. Bertazzo A, Ragazzi E, Biasiolo M, Costa CV, Allegri G. Enzyme activities involved in tryptophan metabolism along the kynurenine pathway in rabbits. Biochim. Biophys. Acta. 2001; 1527: 167-75.
66. Sardar AM, Reynolds GP. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci. Lett. 1995; 187: 9-12.
67. Du F, Okuno E, Whetsell WO Jr, Köhler C, Schwarcz R. Distribution of quinolinic acid phosphoribosyltransferase in the human hippocampal formation and parahippocampal gyrus. J. Comp. Neurol. 1990; 295: 71-82.
68. During MJ, Freese A, Heyes MP et al. Neuroactive metabolites of 1-tryptophan, serotonin and quinolinic acid, in striatal extracellular fluid. Effect of tryptophan loading. FEBS Lett. 1989; 247: 438-44.
69. Habara-Ohkubo A, Takikawa O, Yoshida R. Cloning and expression of a cDNA encoding mouse indoleamine 2,3-dioxygenase. Gene 1991; 105: 221-7.
70. Takikawa O, Habara-Ohkubo A, Yoshida R. IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection. J. Immunol. 1990; 145: 1246-50.
71. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism? Arch. Biochem. Biophys. 1999; 372: 1-7.
72. Heyes MP, Gravell M, London WT et al. Sustained increases in cerebrospinal fluid quinolinic acid concentrations in rhesus macaques (Macaca mulatta) naturally infected with simian retrovirus type-D. Brain Res. 1990; 531: 148-58.
73. Melillo G, Cox GW, Radzioch D, Varesio L. Picolinic acid, a catabolite of 1-tryptophan, is a costimulus for the induction of reactive nitrogen intermediate production in murine macrophages. J. Immunol. 1993; 150: 4031-40.
74. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase. J. Exp. Med 2002; 196: 459-48.
75. Hayaishi O, Yoshida R. Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. Ciba. Found. Symp. 1978; 199-203.
76. Hirata F, Hayaishi O. Studies on indoleamine 2,3-dioxygenase. I. Superoxide anion as substrate. J. Biol. Chem. 1975; 250: 5960-6.
77. Pfefferkom ER, Eckel M, Rebhun S. Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan. Mol. Biochem. Parasitol. 1986; 20: 215-24.
78. Schroten H, Spors B, Hucke C et al. Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase. Neuropediatrics 2001; 32: 206-10.
79. Byrne GI, Lehmann LK, Kirschbaum JG, Borden EC, Lee CM, Brown RR. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J. Interferon Res. 1986; 6: 389-96.
80. Friberg M, Jennings R, Alsarraj M et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002; 101: 151-5.
81. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
82. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 1999; 20: 469-73.
83. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002; 107: 452-60.
84. Ogata S, Takeuchi M, Fujita H, Shibata K, Okumura K, Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 cells. Biosci. Biotechnol. Biochem. 2000; 64: 327-32.
85. Morita T, Saito K, Takemura M et al. 3-Hydroxyanthranilic acid, an 1-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma. Ann. Clin. Biochem. 2001; 38: 242-51.
86. Sarsero JP, Merino E, Yanofsky C. A Bacillus subtilis operon containing genes of unknown function senses tRNATrp charging and regulates expression of the genes of tryptophan biosynthesis. Proc. Natl Acad. Sci. USA 2000; 97: 2656-61.
87. Fleckner J, Martensen PM, Tolstrup AB, Kjeldgaard NO, Justesen J. Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in ceil lines. Cytokine 1995; 7: 70-7.
88. Barcelo-Batllori S, Andre M, Servis C et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: Implications for inflammatory bowel diseases. Proteomics 2002; 2: 551-60.
89. Xie G, Bonner CA, Jensen RA. Dynamic diversity of the tryptophan pathway in chlamydiae: reductive evolution and a novel operon for tryptophan recapture. Genome Biol. 2002; 3: Research 0051.
90. Sanni LA, Thomas SR, Tattam BN et al. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am. J. Pathol. 1998; 152: 611-19.
91. Mehta SJ, Miller RD, Ramirez JA, Summersgill JT. Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon-gamma: role of tryptophan catabolism. J. Infect. Dis. 1998; 177: 1326-31.
92. Fujigaki S, Saito K, Takemura M et al. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect. Immun. 2002; 70: 779-86.
93. MacKenzie CR, Langen R, Takikawa O, Daubener W. Inhibition of indoleamine 2,3-dioxygenase in human macrophages inhibits interferon-gamma-induced bacteriostasis but does not abrogate toxoplasmastasis. Eur. J. Immunol. 1999; 29: 3254-61.
94. Terness P, Bauer TM, Rose L et al. Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase-expressing Dendritic Cells: Mediation of Suppression by Tryptophan Metabolites. J. Exp. Med. 2002; 196: 447-57.
95. Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem. 1986; 261: 3648-53.
96. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219: 316-18.
97. Murray MF, Nghiem M, Srinivasan A. HIV infection decreases intracellular nicotinamide adenine dinucleotide [NAD]. Biochem. Biophys. Res. Commun. 1995; 212: 126-31.
98. Baggiolini M, Wymann MP. Turning on the respiratory burst. Trends. Biochem. Sci. 1990; 15: 69-72.
99. Sun Y. Indoleamine 2,3-dioxygenase - a new antioxidant enzyme. Mater. Med. Pol. 1989; 21: 244-50.
100. Carson DA, Seto S, Wasson DB, Carrera CJ. DNA strand breaks, NAD metabolism, and programmed cell death. Exp. Cell Res. 1986; 164: 273-81.
101. Hageman GJ, Stierum RH. Niacin, poly (ADP-ribose) polymerase-1 and genomic stability. Mutat. Res. 2001; 475: 45-56.
102. Satoh MS, Poirier GG, Lindahl T. Dual function for poly (ADP-ribose) synthesis in response to DNA strand breakage. Biochemistry 1994; 33: 7099-106.
103. Ikai K, Ueda K, Fukushima M, Nakamura T, Hayaishi O. Poly (ADP-ribose) synthesis, a marker of granulocyte differentiation. Proc. Natl Acad. Sci. USA 1980; 77: 3682-5.
104. Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. Mol. Cell Biochem. 1999; 193: 69-74.
105. Liu ZX, Yu Y, Dennert G. A cell surface ADP-ribosyltransferase modulates T cell receptor association and signaling. J. Biol. Chem. 1999; 274: 17 399-401.
106. Liu ZX, Azhipa O, Okamoto S, Govindarajan S, Dennert G. Extracellular nicotinamide adenine dinucleotide induces t cell apoptosis in vivo and in vitro. J. Immunol. 2001; 167: 4942-7.
107. Klaidman LK, Mukherjee SK, Adams JD Jr. Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide. Biochim. Biophys. Acta 2001; 1525: 136-48.
108. Namboodiri MA, Venkateshan CN, Narayanan R et al. Increased quinolinate immunoreactivity in the peripheral blood monocytes/macrophages from SIV-infected monkeys. J. Neurovirol. 1996; 2: 433-8.
109. Foster AC, Schwarcz R. Characterization of quinolinic acid phosphoribosyltransferase in human blood and observations in Huntington's disease. J. Neurochem. 1985; 45: 199-205.
110. Morrison PF, Morishige GM, Beagles KE, Heyes MP. Quinolinic acid is extruded from the brain by a probenecid-sensitive carrier system: a quantitative analysis. J. Neurochem. 1999; 72: 2135-44.
111. Ruffmann R, Welker RD, Saito T, Chirigos MA, Varesio L. In vivo activation of macrophages but not natural killer cells by picolinic acid (PLA). J. Immunopharmacol. 1984; 6: 291-304.
112. Ruffmann R, Schlick R, Chirigos MA, Budzynsky W, Varesio L. Antiproliferative activity of picolinic acid due to macrophage activation. Drugs Exp. Clin. Res. 1987; 13: 607-14.
113. Melillo G, Cox GW, Biragyn A, Sheffler LA, Varesio L. Regulation of nitric-oxide synthase mRNA expression by interferon-gamma and picolinic acid. J. Biol. Chem. 1994; 269: 8128-33.
114. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and-1 beta in macrophages. J. Immunol. 2000; 164: 3283-91.
115. Murray HW, Szuro-Sudol A, Wellner D et al. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect. Immun. 1989; 57: 845-9.
116. Friberg M, Jennings R, Alsarraj M et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002; 101: 151-5.
117. Heyliger SO, Mazzio EA, Soliman KF. The anti-inflammatory effects of quinolinic acid in the rat. Life Sci. 1999; 64: 1177-87.
118. Ogata S, Takeuchi M, Fujita H, Shibata K, Okumura K, Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 cells. Biosci. Biotechnol. Biochem. 2000; 64: 327-32.
119. Fallarino F, Grohmann U, Vacca C et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002; 9: 1069-77.
120. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J. Exp. Med. 2002; 196: 999-1005.
121. Von Bubnoff D, Matz H, Frahnert C et al. FcepsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J. Immunol. 2002; 169: 1810-16.
122. Thompson AG, Thomas R. Induction of immune tolerance by dendritic cells: Implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol. Cell Biol. 2002; 80: 509-19.
123. Belz GT, Heath WR, Carbone FR. The role of dendritic cell subsets in selection between tolerance and immunity. Immunol. Cell Biol. 2002; 80: 463-8.
124. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 2002; 80: 477-83.
125. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-1g regulates tryptophan catabolism in vivo. Nat. Immunol. 2002; 3: 1097-101.
126. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002; 129: 186-96.
127. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 2002; 8: 567-73.
128. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J. Neurochem. 1996; 66: 996-1004.
129. Von Bubnoff D, Matz H, Cazenave JP, Hanau D, Bieber T, de la SH. Kinetics of gene induction after FcepsilonRI ligation of atopic monocytes identified by suppression subtractive hybridization. J. Immunol. 2002; 169: 6170-7.
130. Fukuoka S, Ishiguro K, Yanagihara K et al. Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD). A key enzyme for the tryptophan-niacine pathway and 'quinolinate hypothesis'. J. Biol. Chem. 2002; 277: 35 162-7.
131. Guillemin GJ, Kerr SJ, Smythe GA, Armati PJ, Brew BJ. Kynurenine pathway metabolism in human astrocytes. Adv. Exp. Med. Biol. 1999; 467: 125-31.
132. Guillemin GJ, Smith DG, Kerr SJ et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox. Report 2000; 5: 108-11.
133. Guillemin GJ, Kerr SJ, Smythe GA et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 2001; 78: 842-53.